Track TetraLogic Pharmaceuticals's long-term debt ($31M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2016), TLOG shows a long-term debt of $31M. That compares with $29M in the prior-year period — up 6.9% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TLOG's long-term debt is now $31M (was $29M) — a 6.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether TetraLogic Pharmaceuticals is outperforming or lagging.
Tracking TLOG's long-term debt over time shows whether TetraLogic Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $31M That compares with $29M in the prior-year period — up 6.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has TetraLogic Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $31M) with ownership activity and broader fundamentals.
TetraLogic Pharmaceuticals's long-term debt is $31M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.